|
|
||||||||
From the Department of Neurology (Drs. Schiller and Jung), University Hospital Zürich; Laboratory of Pediatrics and Neurology (Drs. Wevers and Steenbergen), University Medical Center, Nijmegen, The Netherlands; and Division of Clinical Chemistry and Biochemistry (Dr. Blau), University Childrens Hospital, Zürich, Switzerland.
Address correspondence and reprint requests to Dr. Hans H. Jung, Department of Neurology, University Hospital Zürich, Frauenklinikstrasse 26, 8091 Zürich, Switzerland; e-mail: hans.jung{at}usz.ch
The authors report the long-term course of two siblings with L-dopa responsive dystonia (DRD) associated with a compound heterozygous mutation in the tyrosine hydroxylase (TH) gene. Both siblings manifested with lower-limb onset generalized DRD and had a sustained response to low-dose L-dopa therapy for over 35 years. Although the L-dopa therapy was delayed up to 20 years after disease onset, there were no cognitive or neurologic sequelae of the long-term catecholamine deficit.
Received March 26, 2004. Accepted in final form June 2, 2004.
This article has been cited by other articles:
![]() |
F. Clot, D. Grabli, C. Cazeneuve, E. Roze, P. Castelnau, B. Chabrol, P. Landrieu, K. Nguyen, G. Ponsot, M. Abada, et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia Brain, July 1, 2009; 132(7): 1753 - 1763. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |